GlycoMimetics, Inc. (GLYC) Receives Consensus Recommendation of “Buy” from Analysts
Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) have received a consensus rating of “Buy” from the nine research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $17.33.
A number of research firms have weighed in on GLYC. Zacks Investment Research lowered GlycoMimetics from a “hold” rating to a “sell” rating in a research note on Monday, August 7th. BidaskClub upgraded GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. SunTrust Banks, Inc. set a $21.00 target price on GlycoMimetics and gave the stock a “buy” rating in a research note on Monday, August 7th. Stifel Nicolaus reiterated a “buy” rating and issued a $17.00 target price (up previously from $13.00) on shares of GlycoMimetics in a research note on Friday, August 4th. Finally, ValuEngine upgraded GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st.
WARNING: This story was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/18/glycomimetics-inc-glyc-receives-consensus-recommendation-of-buy-from-analysts.html.
In other news, SVP Helen M. Thackray sold 2,000 shares of the firm’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $13.00, for a total transaction of $26,000.00. Following the transaction, the senior vice president now owns 150,615 shares in the company, valued at $1,957,995. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 43.80% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd increased its stake in shares of GlycoMimetics by 43.7% during the third quarter. Dynamic Technology Lab Private Ltd now owns 18,974 shares of the biotechnology company’s stock valued at $265,000 after buying an additional 5,767 shares during the period. Alyeska Investment Group L.P. increased its stake in shares of GlycoMimetics by 2.6% during the third quarter. Alyeska Investment Group L.P. now owns 358,962 shares of the biotechnology company’s stock valued at $5,022,000 after buying an additional 8,962 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of GlycoMimetics during the third quarter valued at $173,000. Russell Investments Group Ltd. increased its stake in shares of GlycoMimetics by 172.4% during the second quarter. Russell Investments Group Ltd. now owns 31,379 shares of the biotechnology company’s stock valued at $350,000 after buying an additional 19,859 shares during the period. Finally, Citadel Advisors LLC purchased a new position in shares of GlycoMimetics during the second quarter valued at $249,000. Hedge funds and other institutional investors own 92.47% of the company’s stock.
Shares of GlycoMimetics (NASDAQ GLYC) traded up $0.09 on Monday, reaching $12.27. The company had a trading volume of 177,440 shares, compared to its average volume of 945,483. GlycoMimetics has a 12 month low of $3.82 and a 12 month high of $16.94.
GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. analysts anticipate that GlycoMimetics will post -1.15 EPS for the current year.
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
Receive News & Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.